Published in final edited form as:

Org Lett. 2010 July 2; 12(13): 2982–2985. doi:10.1021/ol1010032.

Electrophilic Aromatic Selenylation: New OPRT Inhibitors

Mohannad Abdo^a, Yong Zhang^b, Vern L. Schramm^b, and Spencer Knapp^{a,*}

^a Department of Chemistry & Chemical Biology, Rutgers – The State University of New Jersey, 610 Taylor Road, Piscataway, New Jersey 08854

^b Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461

Abstract

2-Ethoxyethaneseleninic acid reacts with electron rich aromatic substrates to deliver, by way of the selenoxides, the (2-ethoxyethyl) seleno ethers, which can in turn be transformed into a diverse set of aryl selenylated products. Among these, a family of 5-uridiny derivatives shows sub-micromolar inhibition of human and malarial orotate phosphoribosyltransferase.

A wide assortment of selenium based reagents allows the introduction of Se into organic structures by both nucleophilic and electrophilic pathways, and the resulting organoselenium products can be oxidized, reduced, or otherwise converted to useful targets that may or may not retain Se.¹ Despite the toxic nature of organoselenium derivatives in general, many of these have shown marked biological and enzyme inhibitory activities that may find important applications.² Electrophilic introduction of Se is commonly performed by using selenenyl chlorides and their relatives, and is mostly limited to ArSe–X examples. We recently demonstrated that alkaneseleninic acids (RSeO₂H) react as electrophiles toward electron rich aromatic rings such as phenols and indoles.^{3,4} We have now modified this reaction to allow the incorporation of the versatile 2-ethoxyethaneselenenyl substituent, and show that transformations of the latter can, in the case of 5-selenylated uridine, produce products that are inhibitory to malarial and human orotate phosphoribosyltransferase.

2-Ethoxyethaneseleninic acid (**1**, Scheme 1), prepared from bromoethyl ethyl ether, reacts with uridine triacetate **2** under acidic conditions (catalytic trifluoroacetic acid) to give as the major product the 5-selenylated nucleoside **3**.⁵ The 5-selenylated pyrimidines **4–6** were prepared analogously.

Would this selenylation reaction work in aqueous solution? Water soluble nucleosides did indeed give the 5-selenylated products **8**, **9**, and **10**, and cytosine gave **6**, when the reaction was performed in the presence of heptafluorobutanoic acid (bp 120 °C), Scheme 2. Deacetylation of the nucleoside triacetates from Scheme 1 confirmed their structures.

spencer.knapp@rutgers.edu.

Supporting Information Available: Details of the enzymatic evaluation, and the preparation and spectroscopic characterization for all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

More reactive aromatic rings, such as those contained in tyrosine and tryptophan, selenylated more easily, even without added acid catalyst (Scheme 3). Less reactive rings, such as those in phenylalanine derivatives, did not selenylate.

By altering the oxidation state and substitution at Se, selenoethers can be transformed to a variety of related organoselenium species. Thus, DMDO oxidation of **3** (Scheme 4) led cleanly to the stable selenoxide **14** (two diastereomers at Se) or, with additional reagent, the selenone **18**. Retro-ene elimination of ArSeOH,⁶ normally spontaneous at 23 °C, is suppressed by the *beta* heteroatom in the ethoxyethyl chain.⁷ Nucleophilic dealkylation of **18** with sodium azide⁸ gave the uridine 5-seleninic acid **20**. Respective deacetylation of **14** and **20** gave the triols **16** and **22**, and, in the analogous 2'-deoxy series, **15** and **21** gave diols **17** and **23**.

Because of the susceptibility of phenols to oxidation, comparable transformations of **12** could only be accomplished following protection of the phenolic –OH (Scheme 5). The selenoxide **25** and selenone **26** were prepared as before, and dealkylation gave the seleninate **27**. Analogous oxidation of **13** was unsuccessful.

Careful purification of product mixtures and identification of minor products allowed some insight into the mechanism of selenylation (Scheme 6). Reaction of **2** gave, in addition to **3**, the diselenides **28**, **29**, and **30**. By subjecting selenoxide **14** to the same conditions, we were able to isolate selenoether **3** and a different mix of **28**, **29**, and **30**. Diselenide **28** results from reductive coupling⁹ of ArSeOH, the product of retro-ene elimination from **14**, and **29** and **30** result from reductive coupling of **1** and diselenide scrambling,¹⁰ respectively. These results strongly implicate selenoxide **14** as an intermediate in the selenylation of **2**. Formation of **14** could arise from initial addition of electrophilic EtOCH₂CH₂Se(OH)₂⁺, followed by loss of water. Reduction of **14** to **3** evidently occurs in part by co-oxidation of seleninate **1** to 2-ethoxyethaneselenonic acid, which then decomposes to 2-ethoxyethanol and SeO₂. The latter was isolated in both reactions, and identified unambiguously by ⁷⁷Se NMR.

Several control reactions (Scheme 7) provide further support for the intermediacy of **14**. Purposeful oxidation of seleninate **1** with DMDO gave SeO₂, as expected. Redox reaction of **14** with didodecyl disulfide (**31**) led to sulfoxide **32** along with **3** (catalytic TFA was required for this reaction), illustrating the ease with which O may be transferred from the selenoxide. However, adding **31** to the reaction of **1** and **2** did not improve the yield, but rather blocked the selenylation by reducing **1**. Finally, thermolysis of **14** in the absence of acid or a reducing agent gave the aldehyde **35**, presumably by way of the retro-ene reaction, followed by efficient re-addition of the selenenic acid **33** to alkene **34**.¹¹ Reduction of **35** and then deacetylation gave the tetrol **36**.

The thermolytic formation of **33** under mild conditions allowed its interception by *i*-Pr₂NH (Scheme 8), providing not the selenenamide,¹² but rather the diselenide **28**. Alternatively, **33** was trapped by dimethylaniline¹³ to give the (mixed) diarylselenide **38**, and **28** was oxidatively cleaved and then coupled to *N*-trimethylsilylimidazole¹⁴ to provide **38**. Respective deacetylation gave 5-selenylated uridines **37**, **29**, and **41**.

Orotate phosphoribosyltransferase (OPRT) is an essential enzyme for the de novo biosynthesis of pyrimidine nucleotides, promoting the attachment of orotic acid to phosphoribosylpyrophosphate.¹⁵ This is the only pathway for pyrimidine nucleotide production in *Plasmodium falciparum*, the major causative agent of malaria.¹⁶ Furthermore, new ways of interrupting nucleotide synthesis in rapidly proliferating human cancer cells may offer alternative therapy options for this disease. The 5-selenated nucleosides were evaluated as competitive inhibitors of malarial and human OPRTs. Six of the relatively non-polar uridine derivatives (**8**, **10**, **36**, **37**, **39**, and **41**) reached sub-micromolar K_i values for

human OPRT (*HsOPRT*), and three of these (**37**, **39**, and **41**) were also sub-micromolar inhibitors of *P. falciparum* OPRT (*PfOPRT*) (Table 1). The most active nucleoside, diselenide **37**, is particularly interesting as it may represent a prototype for OPRT inhibitors that can bind to both subunits of a homodimeric active site. Synthetic access to the selenylated nucleosides also provides new opportunities for investigating the inhibition of additional nucleoside processing enzymes, including pyrimidine nucleoside kinases, thymidine kinase, thymidylate synthetase, thymidine phosphorylase, and orotidine monophosphate decarboxylase.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors are grateful to the Prusoff Foundation for financial support at Rutgers, and to the Rohm and Haas Company for a graduate assistantship to MA. Support at the Albert Einstein College of Medicine was provided by NIH research grants GM41916 and AI049512.

References

1. Iwaoka M, Tomoda S. *Top Curr Chem.* 2000; 208:55–80. Wirth T. *Top Curr Chem.* 2000; 208:1–5. Back, TG. *Organoselenium Chemistry – A Practical Approach.* Oxford Press; New York: 2000.
2. Muges G, du Mont WW, Sies H. *Chem Rev.* 2001; 101:2125–2179. [PubMed: 11710243] Soriano-Garcia M. *Curr Med Chem.* 2001; 11:1657–1669. [PubMed: 15180570] Armishaw CJ, Daly NL, Nevin ST, Adams DJ, Craik DJ, Alewood PF. *J Biol Chem.* 2006; 281:14136–14143. [PubMed: 16500898] Abdo M, Liu S, Zhou B, Walls CD, Knapp S, Zhang ZY. *J Am Chem Soc.* 2008; 130:13196–13197. [PubMed: 18781746] Desai D, Madhunapantula SV, Gowdahalli K, Sharma A, Chandagaludoreswamy R, El-Bayoumy K, Robertson GP, Amin S. *Bioorg Med Chem Lett.* 2010; 20:2038–2043. and references cited therein. [PubMed: 20153642]
3. Abdo M, Knapp S. *J Am Chem Soc.* 2008; 130:9234–9235. [PubMed: 18576651]
4. Electrophilic aryl selenylations: (phenols) Oddershede J, Henriksen L, Larsen S. *Org Biomol Chem.* 2003; 1:1053–1060. [PubMed: 12929647] and references cited therein. (indoles) Crich D, Davies JW. *Tetrahedron Lett.* 1989; 30:4307–4308. and references cited therein.
5. Other uridine selenylations: Choi S, Kalman TI, Bardos TJ. *J Med Chem.* 1979; 22:618–621. [PubMed: 110931] Schinazi R, Arbiser J, Lee J, Kalman T, Prusoff W. *J Med Chem.* 1986; 29:1293–1295. [PubMed: 3027329] Lee CH, Kim YH. *Tetrahedron Lett.* 1991; 32:2401–2404. Goudgaon NM, Naguib FNM, el Kouni MH, Schinazi RF. *J Med Chem.* 1993; 36:4250–4254. [PubMed: 8277507] Roh KR, Chang HK, Kim YH. *Heterocycles.* 1998; 48:437–444. Hassan AEA, Sheng J, Jiang J, Zhang W, Huang Z. *Org Lett.* 2009; 11:2503–2506. [PubMed: 19469515]
6. Sharpless KB, Lauer RF. *J Am Chem Soc.* 1973; 95:2697–2699.
7. Tiecco M, Testaferri L, Tingoli M, Marini F. *J Org Chem.* 1993; 58:1349–1354. and references cited therein.
8. Tiecco M, Testaferri L, Bagnoli L, Scarponi C, Temperini A, Marini F, Santi C. *Tetrahedron: Asymmetry.* 2007; 18:2758–2767.
9. Reich HJ, Wollowitz S, Trend JE, Chow F, Wendelborn DF. *J Org Chem.* 1978; 43:1697–1705.
10. Pleasants JC, Guo W, Rabenstein DL. *J Am Chem Soc.* 1989; 111:6553–6558.
11. Reich HJ, Jasperse CP. *J Org Chem.* 1988; 53:2390–2392.
12. Reich HJ, Renga JM. *J Org Chem.* 1975; 40:3313–3314.
13. Gassman PG, Miura A, Miura T. *J Org Chem.* 1982; 47:951–954.
14. Back TG, Kerr RG. *Can J Chem.* 1986; 64:308–310.
15. Zhang Y, Luo M, Schramm VL. *J Am Chem Soc.* 2009; 131:4685–4694. [PubMed: 19292447] Jones ME. *Ann Rev Biochem.* 1980; 49:253–279. [PubMed: 6105839] Gero AM, O'Sullivan WJ. *Bood Cells.* 1990; 16:467–484.

16. Krungkrai SR, Aoki S, Palacpac NMQ, Sato D, Mitamura T, Krungkrai J, Horii T. Mol Biochem Parasitol. 2004; 134:245–255. [PubMed: 15003844] Bello AM, Poduch E, Liu Y, Wei L, Crandall I, Wang X, Dyanand C, Kain KC, Pai EF, Kotra LP. J Med Chem. 2008; 51:439–448. [PubMed: 18189347]

Scheme 1.
Electrophilic Selenylation with $\text{EtOCH}_2\text{CH}_2\text{SeO}_2\text{H}$

Scheme 2.
Selenylation in Aqueous Solution

Scheme 3.
Selenylation of tyrosine and tryptophan derivatives

Scheme 4.
Oxidation of 5-Selenylated Nucleosides

Scheme 5.
Oxidation of Selenylated Tyrosine Derivative

Scheme 6.
Full Product Analysis of Selenylation Reactions

Scheme 8.
Transformations of ArSeOH

Table 1

Inhibition of OPRTs by Selenylated Nucleosides

compound	K_i , μM (<i>Pf</i> OPRT)	K_i , μM (<i>Hs</i> OPRT)
6	2.15 ± 0.75	1.14 ± 0.48
8	1.30 ± 0.33	0.26 ± 0.03
10	1.44 ± 0.44	0.44 ± 0.10
16	6.10 ± 1.60	2.40 ± 0.39
22	10.82 ± 1.98	5.89 ± 1.31
36	1.54 ± 0.47	0.72 ± 0.21
37	0.16 ± 0.02	0.16 ± 0.03
39	0.75 ± 0.21	0.24 ± 0.10
41	0.92 ± 0.28	0.91 ± 0.27